India Gout Market

ID: MRFR/HC/47506-HCR
200 Pages
Vikita Thakur
Last Updated: April 06, 2026
India Gout Market Research Report By Treatment and Diagnosis (Diagnosis, Treatment, NSAIDs, Corticosteroids, Colchicine, Urate-Lowering Agents, Others), By Application (Acute Gout, Chronic Gout) andBy End User (Hospitals & Clinics, Specialty Centers, Others) - Growth & Industry Forecast 2025 To 2035
India Gout Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)11.75%
2024 Market Size$ 226.63 Million
2025 Market Size$ 253.26 Million
2035 Market Size$ 769.2 Million
Key Players
AstraZeneca
Novartis
Pfizer
Teva Pharmaceutical Industries
Horizon Therapeutics
AbbVie
Opportunities
  • Increasing Prevalence of Gout
  • Rising Healthcare Expenditure
  • Advancements in Diagnostic Techniques
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Construction, BY Treatment (USD Million)
      1. 4.1.1 NSAIDs
      2. 4.1.2 Corticosteroids
      3. 4.1.3 Colchicine
      4. 4.1.4 Urate-Lowering Agents
      5. 4.1.5 Others
    2. 4.2 Construction, BY Application (USD Million)
      1. 4.2.1 Acute Gout
      2. 4.2.2 Chronic Gout
    3. 4.3 Construction, BY End User (USD Million)
      1. 4.3.1 Hospitals & Clinics
      2. 4.3.2 Specialty Centers
      3. 4.3.3 Others
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Construction
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Construction
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 AstraZeneca (GB)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Novartis (CH)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Pfizer (US)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Teva Pharmaceutical Industries (IL)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Horizon Therapeutics (IE)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 AbbVie (US)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Sanofi (FR)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Bristol-Myers Squibb (US)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 INDIA MARKET ANALYSIS BY TREATMENT
    3. 6.3 INDIA MARKET ANALYSIS BY APPLICATION
    4. 6.4 INDIA MARKET ANALYSIS BY END USER
    5. 6.5 KEY BUYING CRITERIA OF CONSTRUCTION
    6. 6.6 RESEARCH PROCESS OF MRFR
    7. 6.7 DRO ANALYSIS OF CONSTRUCTION
    8. 6.8 DRIVERS IMPACT ANALYSIS: CONSTRUCTION
    9. 6.9 RESTRAINTS IMPACT ANALYSIS: CONSTRUCTION
    10. 6.10 SUPPLY / VALUE CHAIN: CONSTRUCTION
    11. 6.11 CONSTRUCTION, BY TREATMENT, 2024 (% SHARE)
    12. 6.12 CONSTRUCTION, BY TREATMENT, 2024 TO 2035 (USD Million)
    13. 6.13 CONSTRUCTION, BY APPLICATION, 2024 (% SHARE)
    14. 6.14 CONSTRUCTION, BY APPLICATION, 2024 TO 2035 (USD Million)
    15. 6.15 CONSTRUCTION, BY END USER, 2024 (% SHARE)
    16. 6.16 CONSTRUCTION, BY END USER, 2024 TO 2035 (USD Million)
    17. 6.17 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 India MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY TREATMENT, 2025-2035 (USD Million)
      2. 7.2.2 BY APPLICATION, 2025-2035 (USD Million)
      3. 7.2.3 BY END USER, 2025-2035 (USD Million)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

India Gout Market Segmentation

India Gout Market By Treatment (USD Million, 2025-2035)

  • NSAIDs
  • Corticosteroids
  • Colchicine
  • Urate-Lowering Agents
  • Others

India Gout Market By Application (USD Million, 2025-2035)

  • Acute Gout
  • Chronic Gout

India Gout Market By End User (USD Million, 2025-2035)

  • Hospitals & Clinics
  • Specialty Centers
  • Others
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.